Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Champions Oncology ( (CSBR) ).
On March 24, 2026, Champions Oncology, Inc., a global oncology-focused research services provider, reported that its Board accepted the resignation of director Dr. Philip Breitfeld and appointed Brian Alexander, MD, MPH, to fill the resulting vacancy. The company noted that Breitfeld’s departure did not stem from any disagreement over operations or policies, and that there are no special arrangements or related-party transactions tied to Alexander’s appointment.
Announced publicly on March 30, 2026, the move underscores Champions’ push to deepen its data-driven oncology strategy by linking its large portfolio of patient-derived tumor models with rich molecular and clinical datasets. Alexander’s background in oncology, data science, and AI-enabled drug development at organizations such as Valo Health, Flagship Pioneering, and Foundation Medicine is expected to strengthen the firm’s efforts to build a more connected translational research platform, potentially enhancing its value proposition for biopharma partners and reinforcing its position in data-centric oncology R&D.
The most recent analyst rating on (CSBR) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Champions Oncology stock, see the CSBR Stock Forecast page.
Spark’s Take on CSBR Stock
According to Spark, TipRanks’ AI Analyst, CSBR is a Neutral.
The score is held back primarily by deteriorating TTM operating performance (revenue decline, margin compression, and losses) and a bearish technical trend. These are only partly offset by relatively resilient cash flow/leverage and a moderately positive earnings outlook centered on full-year growth and positive adjusted EBITDA, while valuation remains challenging due to a very high P/E.
To see Spark’s full report on CSBR stock, click here.
More about Champions Oncology
Champions Oncology, Inc. is a global preclinical and clinical research services provider focused on oncology, offering end-to-end R&D solutions to biopharma organizations. The company operates one of the largest and most annotated banks of patient-derived xenograft and primary hematological malignancy models, leveraging proprietary in vivo, ex vivo, and bioanalytical platforms to generate high-quality data for oncology drug discovery and development.
Its strategy centers on an integrated platform built around patient-derived tumor models, enriched with comprehensive molecular and clinical datasets to enable advanced analytics and AI-driven insights. This data-informed approach is designed to support partners across the oncology R&D continuum, positioning Champions as a leading translational oncology research organization in a rapidly evolving, data-centric market.
Average Trading Volume: 7,321
Technical Sentiment Signal: Sell
Current Market Cap: $79.71M
For an in-depth examination of CSBR stock, go to TipRanks’ Overview page.